Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TEMOZOLOMIDE Cause Therapy partial responder? 169 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 169 reports of Therapy partial responder have been filed in association with TEMOZOLOMIDE (TEMOZOLOMIDE). This represents 1.0% of all adverse event reports for TEMOZOLOMIDE.

169
Reports of Therapy partial responder with TEMOZOLOMIDE
1.0%
of all TEMOZOLOMIDE reports
47
Deaths
6
Hospitalizations

How Dangerous Is Therapy partial responder From TEMOZOLOMIDE?

Of the 169 reports, 47 (27.8%) resulted in death, 6 (3.6%) required hospitalization, and 5 (3.0%) were considered life-threatening.

Is Therapy partial responder Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TEMOZOLOMIDE. However, 169 reports have been filed with the FAERS database.

What Other Side Effects Does TEMOZOLOMIDE Cause?

Disease progression (1,562) Death (1,403) Off label use (1,357) Product use in unapproved indication (1,353) Thrombocytopenia (1,300) Drug ineffective (1,131) Nausea (1,071) Neutropenia (809) Malignant neoplasm progression (779) Fatigue (766)

What Other Drugs Cause Therapy partial responder?

CYCLOPHOSPHAMIDE (1,397) RITUXIMAB (1,219) DEXAMETHASONE (1,199) PREDNISONE (1,176) PEMBROLIZUMAB (1,125) CARBOPLATIN (1,096) DOXORUBICIN (834) METHOTREXATE (775) VINCRISTINE (707) ETOPOSIDE (670)

Which TEMOZOLOMIDE Alternatives Have Lower Therapy partial responder Risk?

TEMOZOLOMIDE vs TEMSIROLIMUS TEMOZOLOMIDE vs TENAMFETAMINE TEMOZOLOMIDE vs TENAPANOR TEMOZOLOMIDE vs TENECTEPLASE TEMOZOLOMIDE vs TENELIGLIPTIN

Related Pages

TEMOZOLOMIDE Full Profile All Therapy partial responder Reports All Drugs Causing Therapy partial responder TEMOZOLOMIDE Demographics